

PEXA receives order from German Federal Institute BAuA for second instrument

PEXA AB announces that it has received an order from the German Federal Institute for Occupational Safety and Health (BAuA) for a second PEXA instrument. The system will be used in ongoing research focusing on airborne particles and respiratory infections.

BAuA has been a user of PEXA technology for several years, and this follow-on order reflects a continued commitment to the methodology. The instrument will support an ongoing research project aimed at increasing the understanding of bioaerosols and their role in indoor environments. The next phase of the project will include sampling of patients with respiratory infections, building on earlier studies conducted in healthy individuals.

BAuA has previously published research using PEXA technology to study aerosol formation and emission from the human respiratory tract, contributing to increased understanding of airborne transmission and occupational exposure.

- *The PEXA technology enables us to study particles in exhaled air in a non-invasive way, which is highly relevant for understanding bioaerosols and airborne transmission. We have used the technology in previous research, and we now look forward to extending the work to patients with respiratory infections, says Dr. Susann Meyer, BAuA.*

PEXA is currently experiencing growing interest from occupational health institutes, government agencies, and academic research environments. Non-invasive access to the small airways enables new approaches to studying airborne exposure and respiratory health.

- *We are very pleased to continue our collaboration with BAuA. Their work is highly relevant in today's context, where understanding airborne transmission and occupational exposure is increasingly important. This order is a strong validation of the value of our technology in this field, says Tomas Gustafsson, CEO of PEXA.*

Customers and users in this segment include national institutes such as BAuA (Germany), NIOSH (USA), and STAMI (Norway), as well as research groups at universities including Örebro University (Sweden), the University of Gothenburg (Sweden), and Aarhus University (Denmark). This reflects a broader trend of increased focus on occupational exposure and respiratory disease.

Further information about the BAuA project can be found here: <https://www.baua.de/EN/Research/Research-projects/f2584>

For further information, please contact:

Tomas Gustafsson, CEO, info@pexa.se

About PExA AB:

PExA AB PExA AB (556956-9246) has developed the PExA 2.1, a patented research instrument that helps researchers intelligently collect biological samples from the smallest airways through a simple exhalation maneuver. PExA's technology is currently used by prominent research groups in several different countries and research with the instrument has resulted in approximately 50 scientific publications, which serve as reference material for PExA's method. The company's long-term goal is to market and sell diagnostic instruments for popular diseases (e.g. lung cancer and COPD) to be used globally for diagnosis or general screening at facilities where care is offered. The company intends at the time it is relevant to sell to clinics to have developed more patient-friendly, flexible and commercial products, which means that PExA addresses a significantly wider market, which today includes several million patients globally.

PExA's B share is listed on the Spotlight Stock Market.